(Q24247243)

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Effect of macrolides on in vivo ion transport across cystic fibrosis nasal epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Azithromycin: an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Molecular insights into the physiology of the 'thin film' of airway surface liquid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Diffuse panbronchiolitis and cystic fibrosis: East meets West

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Pathogenicity of microbes associated with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Prophylactic anti-staphylococcal antibiotics for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Daily versus weekly azithromycin in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Long-term azithromycin may improve lung function in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Therapeutic possibilities for diffuse panbronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Anti-inflammatory activity of macrolides: a new therapeutic potential?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2

Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB2